Efferon CT hemoadsorption for cardiogenic shock after a heart attack

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses the Efferon CT hemoadsorption device to remove cytokines and other pro‑inflammatory molecules (≤55 kDa) from the blood of patients with cardiogenic shock complicating acute myocardial infarction. Treatment is started early (within 4 hours of shock diagnosis) in patients with SCAI stages B–C who can receive at least 4 hours of therapy, and outcomes such as organ dysfunction scores, inflammatory markers, hemodynamic stability, and short‑term survival will be tracked. The rationale builds on prior hemoadsorption work (for example CytoSorb) that showed reductions in IL‑6 and improved hemodynamics in acute cardiac settings. The trial is conducted at Tomsk NRMC Cardiology Research Institute and applies standard inclusion and exclusion criteria to limit confounding from non‑AMI causes of shock or very advanced comorbidity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Not more than 4 hours after diagnosis Cardiogenic shock complicating acute myocardial infarction
* Stages B - C of cardiogenic shock according to SCAI
* Patient condition allows treatment with Efferon® CT device for at least 4 hours
* SOFA score 12 or less

Exclusion Criteria:

* Broken-heart syndrome (takotsubo cardiomyopathy)
* Postcardiotomy cardiogenic shock
* Acute myocardial infarction within the last 4 weeks
* Myocarditis
* Cardiac trauma
* Charlson comorbidity index greater than 9 points
* Chronic kidney disease, stage 5 D (requiring continuous hemodialysis)
* Acute pulmonary embolism
* Acute cerebral circulatory collapse
* Transfusion reaction
* Patients on immunosuppressive therapy for cancer and autoimmune diseases
* Pregnancy
* Any other clinical condition of the patient that in the opinion of the investigator precludes inclusion in this study

Where it's running

• Tomsk NRMC Cardiology Research Institute
  Tomsk, Russia Recruiting

Study contacts

• Principal investigator: Vyacheslav Ryabov, PhD, MD — Tomsk NRMC Cardiology Research Institute
• Study coordinator: Alexandr Shelehov-Kravchenko, PhD, MD
• Email: alexandr.shelehov@gmail.com
• Phone: +79636564765

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lowering blood pressure target to reduce noradrenaline use in cardiogenic shock patients

  This study is testing if aiming for a lower blood pressure target can help patients in cardiogenic shock use less medication and improve their chances of survival and kidney health.

  Recruiting Phase 4 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT05168462

• Heart@Home: Safe, at-home care for people with acute heart problems compared with hospital care

  This trial tests whether hospital-level care at home can safely and effectively treat adults with acute heart conditions who would normally be in the hospital.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07913152

• Factors Influencing Outcomes in ECMO and Impella Patients

  This study tests whether metabolic and thyroid hormone changes help predict survival for adults on ECMO or Impella at a single Hungarian cardiac ICU.

  Recruiting Gottsegen National Cardiovascular Institute · Budapest · NCT07885618

• Digital cardiac rehab to help heart attack patients improve function

  A digital health–supported cardiac rehabilitation program is being tested to see if it helps people after a heart attack improve fitness and stay engaged with rehab, compared with standard outpatient rehab.

  Recruiting Cairo University · Minya, Minya Province · NCT07867197

• Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients

  This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.

  Recruiting NIRSense Inc. · Weston, Florida · NCT07825363

• NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa

  This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.

  Recruiting University of Eastern Finland · Savonlinna · NCT07820800

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.